- Fesoterodinefumarate
-
- $5.00 / 1KG
-
2024-04-16
- CAS:286930-03-8
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: g-kg-tons, free sample is available
- Fesoterodinefumarate
-
- $10.00 / 1kg
-
2023-08-22
- CAS:286930-03-8
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 1000tons
- Fesoterodine Fumarate
-
- $10.00 / 1kg
-
2023-02-13
- CAS:286930-03-8
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 50MT
|
| Product Name: | Fesoterodinefumarate | | Synonyms: | (R)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl isobutyrate fumarate;(R)-Fesoterodine fumarate
2-[(1R)-3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate fumarate;(R)-2-(3-(Diisopropylamino)-1-phenylpropyl)-4-methoxyphenyl isobutyrate fumarate;Fesoterodine maleate;2-[(1R)-3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate fumarate;Propanoic acid, 2-methyl-, 2-((1R)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl ester, (2E)-2-butenedioate (1:1) (salt);Spm 8272;Toviaz | | CAS: | 286930-03-8 | | MF: | C30H41NO7 | | MW: | 527.65 | | EINECS: | 639-689-3 | | Product Categories: | Toviaz;Amines;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;Aromatics Compounds | | Mol File: | 286930-03-8.mol |  |
| | Fesoterodinefumarate Chemical Properties |
| Melting point | 72-78°C | | storage temp. | Inert atmosphere,2-8°C | | solubility | DMSO (Slightly), Ethanol (Slightly), Methanol (Slightly) | | form | Solid | | color | White to Off-White | | Stability: | Hygroscopic |
| | Fesoterodinefumarate Usage And Synthesis |
| Description | Fesoterodine fumarate is a new drug for the treatment of overactive bladder syndrome developed by Pfizer, which was approved by the US FDA in October 2008. Fesoterodine fumarate is a prodrug, which is rapidly hydrolyzed in blood after oral administration to 5-hydroxymethyl tolterodine (5-HMT), which is also the active metabolite of tolterodine. | | Biological activity | Fesoterodine Fumarate (SPM 907) is a prodrug of the muscarinic receptor antagonist 5-hydroxymethyl tolterodine, used to treat overactive bladder. | | Side effects | The most common side effects was dry mouth, which was observed in the placebo group, the product 4 in the Phase II and Phase III clinical trials (a total of 2 859 patients, 2 288 taking this product for 8 to 12 weeks). The incidences of dry mouth at mg/d and 8 mg/d were 7%, 19%, and 35%, respectively, and the incidences of drug discontinuation due to dry mouth were 0.4%, 0.4%, and 0.8%, respectively. The second most common adverse reaction was constipation. The incidence of constipation in the placebo group and the 4 mg/d and 8 mg/d groups of this product was 2%, 4% and 6%, respectively. Other reported adverse events included loss of appetite, nausea, epigastric pain, urinary tract infection, upper respiratory tract infection, dry eyes, dysuria, urinary retention, cough, peripheral edema, back pain, insomnia, abnormal liver function, and rash. | | Chemical Properties | White Solid | | Uses | (R)-Fesoterodine Fumarate is a muscarinic receptor antagonist for the treatment of Lower Urininary Tract Symptoms (LUTS). It is very similar to Tolterodine (T535800). | | Uses | Fesoterodine fumarate (Toviaz) is an antimuscarinic agent and is rapidly de-esterified to its active metabolite 5-hydroxymethyl tolterodine that is a muscarinic receptor antagonist. Fesoterodine fumarate (Toviaz) is used to treat the symptoms of overactiv | | Clinical Use | Antimuscarinic:Symptomatic treatment of urinary incontinence,
frequency or urgency | | Drug interactions | Potentially hazardous interactions with other drugs
Anti-arrhythmics: increased risk of antimuscarinic
side effects with disopyramide.
Antifungals: dose reduction advised with
itraconazole and ketoconazole.
Antivirals: dose reduction advised with atazanavir,
indinavir, ritonavir and saquinavir.
Induction of CYP3A4 may lead to subtherapeutic
plasma levels. Concomitant use with CYP3A4
inducers (e.g. carbamazepine, rifampicin,
phenobarbital, phenytoin, St John's Wort) is not
recommended.
Co-administration of a potent CYP2D6 inhibitor
may result in increased exposure and adverse events.
A dose reduction to 4 mg may be needed' | | Metabolism | Rapidly and extensively hydrolysed to its active
metabolite. The active metabolite is further metabolised
in the liver to its carboxy, carboxy-N-desisopropyl, and
N-desisopropyl metabolites via two major pathways
involving CYP2D6 and CYP3A4. None of these
metabolites contribute significantly to the antimuscarinic
activity of fesoterodine. Approximately 70% of an
oral dose of fesoterodine is recovered in the urine as
metabolites, and a smaller amount in the faeces. |
| | Fesoterodinefumarate Preparation Products And Raw materials |
|